表紙
市場調査レポート

難治性慢性リンパ球性白血病:世界の治験レビュー

Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 299735
出版日 ページ情報 英文 198 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
難治性慢性リンパ球性白血病:世界の治験レビュー Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
出版日: 2014年04月15日 ページ情報: 英文 198 Pages
概要

当レポートでは、難治性慢性リンパ球性白血病の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

地域別の治験

  • 国別の治験動向
    • アジア太平洋地域の主要国
    • 欧州の主要国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国における治験:腫瘍科の治験に対する難治性慢性リンパ球性白血病の割合

G7諸国における治験:相別

G7諸国における治験:段階別

E7諸国における治験:腫瘍科の治験に対する難治性慢性リンパ球性白血病の割合

E7諸国における治験:相別

E7諸国における治験:段階別

相別の治験

段階別の治験

評価項目別の治験

未完了の治験

一定期間に採用された被験者

スポンサータイプ別の治験

有望なスポンサー

  • 難治性慢性リンパ球性白血病の治療薬の治験に参加している主要企業

有望薬

最新の治験ニュース

治験プロファイル

  • 主要企業の治験概要
    • F. Hoffmann-La Roche Ltd.
    • Celgene Corporation
    • Pharmacyclics, Inc.
    • Janssen Global Services, LLC
    • GlaxoSmithKline plc
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Sanofi
    • Merck & Co., Inc.
  • 主要大学・研究機関・病院の治験概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • The University of Texas M. D. Anderson Cancer Center
    • Case Comprehensive Cancer Center
    • Roswell Park Cancer Institute
    • Ohio State University Comprehensive Cancer Center
    • Mayo Clinic
    • Beth Israel Deaconess Medical Center
    • Massachusetts General Hospital
    • Duke University

主な臨床プロファイル

付録

図表

目次
Product Code: GDHC2082CTIDB

GlobalData's clinical trial report, "Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Refractory Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Chronic Lymphocytic Leukemia (CLL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Refractory Chronic Lymphocytic Leukemia (CLL)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Refractory Chronic Lymphocytic Leukemia (CLL)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Refractory Chronic Lymphocytic Leukemia (CLL)
    • Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL
    • Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
    • Jun 01, 2009: Trubion Announces Positive Data From A Phase I / II Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL)
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Pharmacyclics, Inc.
      • Clinical Trial Overview of Pharmacyclics, Inc.
      • Janssen Global Services, LLC
      • Clinical Trial Overview of Janssen Global Services, LLC
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Gilead Sciences, Inc.
      • Clinical Trial Overview of Gilead Sciences, Inc.
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Case Comprehensive Cancer Center
      • Clinical Trial Overview of Case Comprehensive Cancer Center
      • Roswell Park Cancer Institute
      • Clinical Trial Overview of Roswell Park Cancer Institute
      • Ohio State University Comprehensive Cancer Center
      • Clinical Trial Overview of Ohio State University Comprehensive Cancer Center
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • Beth Israel Deaconess Medical Center
      • Clinical Trial Overview of Beth Israel Deaconess Medical Center
      • Massachusetts General Hospital
      • Clinical Trial Overview of Massachusetts General Hospital
      • Duke University
      • Clinical Trial Overview of Duke University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014*

List of Figures

  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top